Fetching the paper…
Reading the bibliography…
Contemporary scientific research is a distributed, collaborative endeavor, carried out by teams of researchers, regulatory institutions, funding agencies, commercial partners, and scientific bodies, all interacting with each other and facing different incentives.
Publication decisions and their possible effects on inferences drawn from tests of significance—or vice versa
Theodore D Sterling · 1959
Earlier work this paper cites.
Publication decisions and tests of significance—a comment
Gordon Tullock · 1959
Earlier work this paper cites.
A note on a method for the analysis of significances en masse
Paul Seeger · 1968
Earlier work this paper cites.
False models and post-data model construction
Edward E Leamer · 1974
Earlier work this paper cites.
Combining expert judgments: A Bayesian approach
Peter A Morris · 1977
Earlier work this paper cites.
Controlling the false discovery rate: a practical and powerful approach to multiple testing
Yoav Benjamini and Yosef Hochberg · 1995
Earlier work this paper cites.
21 U.S.C. 301 note
Food and Drug Modernization Act of 1997 · 1997
Earlier work this paper cites.
On the adaptive control of the false discovery rate in multiple testing with independent statistics
Yoav Benjamini and Yosef Hochberg · 2000
Earlier work this paper cites.
Empirical Bayes analysis of a microarray experiment
Bradley Efron, Robert Tibshirani, John D Storey, and Virginia Tusher · 2001
Earlier work this paper cites.
Bayesian methods in meta-analysis and evidence synthesis
Alex J Sutton and Keith R Abrams · 2001
Earlier work this paper cites.
Operating characteristics and extensions of the false discovery rate procedure
Christopher Genovese and Larry Wasserman · 2002
Earlier work this paper cites.
The positive false discovery rate: a Bayesian interpretation and the q q -value
John D Storey · 2003
Earlier work this paper cites.
Probability and finance: it’s only a game! , volume 491
Glenn Shafer and Vladimir Vovk · 2005
Earlier work this paper cites.
Regulatory errors with endogenous agendas
Daniel Carpenter and Michael M Ting · 2007
Earlier work this paper cites.
Selective trials: A principal-agent approach to randomized controlled experiments
Sylvain Chassang, Padró I Miquel, Erik Snowberg, et al · 2012
Earlier work this paper cites.
Large-scale inference: empirical Bayes methods for estimation, testing, and prediction , volume 1
Bradley Efron · 2012
Cited alongside, same era.
Valid post-selection inference
Richard Berk, Lawrence Brown, Andreas Buja, Kai Zhang, and Linda Zhao · 2013
Cited alongside, same era.
Statistical learning and selective inference
Jonathan Taylor and Robert J Tibshirani · 2015
Cited alongside, same era.
Innovation in the pharmaceutical industry: new estimates of R&D costs
Joseph A DiMasi, Henry G Grabowski, and Ronald W Hansen · 2016
Cited alongside, same era.
An economic theory of statistical testing
Aleksey Tetenov · 2016
Cited alongside, same era.
Persuasion bias in science: Can economics help?
Alfredo Di Tillio, Marco Ottaviani, and Peter Norman Sørensen · 2017
Cited alongside, same era.
Critical values robust to p-hacking
Adam McCloskey and Pascal Michaillat · 2020
Later among the works it cites.
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study
Thomas J Moore, James Heyward, Gerard Anderson, and G Caleb Alexander · 2020
Later among the works it cites.
Estimated research and development investment needed to bring a new medicine to market, 2009-2018
Olivier J Wouters, Martin McKee, and Jeroen Luyten · 2020
Later among the works it cites.
A model of scientific communication
Isaiah Andrews and Jesse M Shapiro · 2021
Later among the works it cites.
US Food and Drug Administration reasoning in approval decisions when efficacy evidence is borderline, 2013–2018
Perrine Janiaud, Telba Irony, Estelle Russek-Cohen, and Steven N Goodman · 2021
Later among the works it cites.
alphaXiv searches the wider corpus for related work and actual follow-ups.
alphaXiv is searching for related work…
Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016
Thomas J Moore, Hanzhe Zhang, Gerard Anderson, and G Caleb Alexander · 2018
Cited alongside, same era.
Biopharma’s biggest sellers – the oldies that just keep giving, 2019
Edwin Elmhirst and Lisa Urquhart · 2019
Cited alongside, same era.
Demonstrating substantial evidence of effectiveness for human drug and biological products draft guidance for industry
FDA · 2019
Cited alongside, same era.
Confirmatory trials for drugs approved on a single trial
Alyson Haslam and Vinay Prasad · 2019
Cited alongside, same era.
Research and the approval process: The organization of persuasion
Emeric Henry and Marco Ottaviani · 2019
Cited alongside, same era.
Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design
Leah Isakov, Andrew W Lo, and Vahid Montazerhodjat · 2019
Cited alongside, same era.
How much does it cost to research and develop a new drug? A systematic review and assessment
Michael Schlander, Karla Hernandez-Villafuerte, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz, and Michael Baumann · 2021
Later among the works it cites.
Testing by betting: A strategy for statistical and scientific communication
Glenn Shafer · 2021
Later among the works it cites.
Optimal estimation when researcher and social preferences are misaligned
Jann Spiess · 2021
Later among the works it cites.
(When) should you adjust inferences for multiple hypothesis testing?
Davide Viviano, Kaspar Wuthrich, and Paul Niehaus · 2021
Later among the works it cites.
Preregistration and incentives
Cole Williams · 2021
Later among the works it cites.
Principal-agent hypothesis testing
Stephen Bates, Michael I. Jordan, Michael Sklar, and Jake A. Soloff · 2022
Later among the works it cites.
Which findings should be published?
Alexander Frankel and Maximilian Kasy · 2022
Later among the works it cites.
Experimentation and approval mechanisms
Andrew McClellan · 2022
Later among the works it cites.
Game-theoretic statistics and safe anytime-valid inference
Aaditya Ramdas, Peter Grünwald, Vladimir Vovk, and Glenn Shafer · 2022
Later among the works it cites.
Designing incentives for heterogeneous researchers
Nathan Yoder · 2022
Later among the works it cites.